Related Experiment Video
Updated: Oct 5, 2025
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Immune Checkpoint Inhibition in GBM Primed with Radiation by Engineered Extracellular Vesicles
Tian Tian1, Ruyu Liang1, Gulsah Erel-Akbaba2
1Department of Neurobiology, Key Laboratory of Human Functional Genomics of Jiangsu, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Abstract:
The lack of safe and effective delivery across the blood-brain barrier and the profound immune suppressive microenvironment are two main hurdles to glioblastoma (GBM) therapies. Extracellular vesicles (EVs) have been used as therapeutic delivery vehicles to GBM but with limited efficacy. We hypothesized that EV delivery to GBM can be enhanced by (i) modifying the EV surface with a brain-tumor-targeting cyclic RGDyK peptide (RGD-EV) and (ii) using bursts of radiation for enhanced accumulation. In addition, EVs were loaded with small interfering RNA (siRNA) against programmed cell death ligand-1 (PD-L1) for immune checkpoint blockade. We show that this EV-based strategy dramatically enhanced the targeting efficiency of RGD-EV to murine GBM, while the loaded siRNA reversed radiation-stimulated PD-L1 expression on tumor cells and recruited tumor-associated myeloid cells, offering a synergistic effect. The combined therapy significantly increased CD8+ cytotoxic T cells activity, halting tumor growth and prolonging animal survival. The selected cell source for EVs isolation and the presented functionalization strategy are suitable for large-scale production. These results provide an EV-based therapeutic strategy for GBM immune checkpoint therapy which can be translated to clinical applications.
Insights
This study presents a novel extracellular vesicle (EV) therapy for glioblastoma (GBM). By targeting EVs to brain tumors and loading them with immune-modulating RNA, researchers enhanced treatment efficacy and prolonged survival in preclinical models.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Glioblastoma (GBM) therapy faces challenges with blood-brain barrier penetration and immune suppression.
- Extracellular vesicles (EVs) show promise for GBM drug delivery but have limited efficacy.
- Current GBM treatments require improved targeted delivery and immune modulation strategies.
Purpose of the Study:
- To enhance EV delivery to GBM using a brain-tumor-targeting peptide and radiation.
- To investigate the efficacy of EVs loaded with siRNA against PD-L1 for immune checkpoint blockade.
- To evaluate the synergistic effects of combined EV therapy and radiation on GBM growth and survival.
Main Methods:
- EVs were modified with a cyclic RGDyK peptide (RGD-EV) for enhanced GBM targeting.
- EVs were loaded with small interfering RNA (siRNA) targeting programmed cell death ligand-1 (PD-L1).
- A combination therapy of RGD-EVs and radiation was tested in murine GBM models.
Main Results:
- RGD-EVs demonstrated significantly enhanced targeting efficiency in murine GBM.
- siRNA-loaded EVs reversed radiation-induced PD-L1 expression and recruited tumor-associated myeloid cells.
- The combined therapy increased CD8+ cytotoxic T cell activity, halted tumor growth, and prolonged survival.
Conclusions:
- The developed EV-based strategy is effective for GBM immune checkpoint therapy.
- The functionalization and cell source are suitable for large-scale production and potential clinical translation.
- This approach offers a promising therapeutic strategy for glioblastoma treatment.
